A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT ID: NCT05104866
Last Updated: 2025-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
732 participants
INTERVENTIONAL
2021-10-18
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
NCT05866432
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
NCT00475670
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
NCT01702571
DP303c in Patients With HER2-positive Advanced Breast Cancer
NCT05901935
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
NCT05215106
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be stratified based on number of previous lines of chemotherapy (1 vs. 2), prior use of CDK4/6 inhibitors (Yes vs. no) and geographic region of participant (US/Canada/Europe vs. rest of world).
This study aims to see if datopotamab deruxtecan allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dato-DXd
Arm 1: Dato-DXd
Dato-DXd
Experimental drug. Provided in 100mg vials. IV infusion.
Investigators Choice of Chemotherapy (ICC)
Arm 2: ICC
Capecitabine
Gemcitabine
Eribulin mesylate
Vinorelbine
Capecitabine
Tablet. Oral route of administration. Active comparator
Gemcitabine
IV Infusion. Active comparator
Eribulin
IV Infusion. Active comparator
Vinorelbine
IV Infusion. Active comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dato-DXd
Experimental drug. Provided in 100mg vials. IV infusion.
Capecitabine
Tablet. Oral route of administration. Active comparator
Gemcitabine
IV Infusion. Active comparator
Eribulin
IV Infusion. Active comparator
Vinorelbine
IV Infusion. Active comparator
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Type of Participant and Disease Characteristics
* Inoperable or metastatic HR+, HER2-negative breast cancer
* Progressed on and not suitable for endocrine therapy per investigator assessment and treated with 1 to 2 lines of prior chemotherapy in the inoperable/metastatic setting. Participant must have documented progression on their most recent line of chemotherapy.
* Eligible for one of the chemotherapy options listed as ICC (eribulin, capecitabine, vinorelbine, gemcitabine), per investigator assessment.
* ECOG PS of 0 or 1, with no deterioration over the previous 2 weeks prior to day of first dosing.
* At least 1 measurable lesion not previously irradiated that qualifies as a RECIST 1.1. Note: Participants with bone-only metastases are not permitted.
* Participants with a history of previously treated neoplastic spinal cord compression, or clinically inactive brain metastases, who require no treatment with corticosteroids or anticonvulsants, may be included in the study, if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and study enrolment.
* Adequate organ and bone marrow function within 7 days before day of first dosing as follows:
* Hemoglobin: ≥ 9.0 g/L.
* Absolute neutrophil count: 1500/mm3.
* Platelet count: 100000/mm3. • Total bilirubin: ≤ 1.5 × ULN if no liver metastases; or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.
* ALT and AST: ≤ 3 × ULN for AST/ALT; however, if elevation is due to liver metastases, ≤ 5.0 × ULN is allowed.
* Calculated creatinine clearance: ≥ 30 mL/min as calculated using the Cockcroft-Gault equation (using actual body weight).
* LVEF ≥ 50% by either an echocardiogram or MUGA within 28 days of first dosing.
* Has had an adequate treatment washout period before Cycle 1 Day 1, defined as:
* Major surgery: ≥ 3 weeks.
* Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks).
* Anticancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer).
* Antibody-based anticancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases).
* Immunotherapy (non-antibody-based therapy): ≥ 2 weeks or 5 times the terminal elimination T½ of the agent, whichever is longer.
* Chloroquine/hydroxychloroquine: \> 14 days.
* Have available a FFPE tumor sample (block preferred, or a minimum of 20 freshly cut slides), at the time of screening. Note: Sample collection in China will comply with local regulatory approval.
* Minimum life expectancy of 12 weeks at screening.
Sex
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; (oral estrogens are not permitted).
Reproduction
* Negative pregnancy test (serum) for women of childbearing potential
* Female participants must be post-menopausal for at least 1 year, surgically sterile, or using one highly effective form of birth control. Female participants must refrain from egg cell donation and breastfeeding while on study and for at least 7 months after the last dose of study intervention. Non-sterilized male partners of a woman of childbearing potential must use a male condom plus spermicide throughout this period.
* Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using a highly effective method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 4 months after the last dose of study intervention) to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female partners of male participants are allowed to use HRT for contraception.
Informed Consent
* Capable of giving signed informed consent.
* Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative.
Exclusion Criteria
* Any evidence of diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy, adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated.
* Persistent toxicities caused by previous anticancer therapy (excluding alopecia), not yet improved to CTCAE Version 5.0 Grade ≤ 1 or baseline. Note: participants may be enrolled with some chronic, stable Grade 2 toxicities (defined as no worsening to \> Grade 2 for at least 3 months prior to first dosing and managed with SoC treatment) which the investigator deems related to previous anticancer therapy.
* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections.
* Known active or uncontrolled hepatitis B or C infection; or positive for hepatitis B or C virus based on the evaluation of results of tests for hepatitis B (HBsAg, anti-HBs, anti-HBc, or HBV DNA) or hepatitis C (HCV antibody or HCV RNA) infection at screening.
* Known HIV infection that is not well controlled.
* Uncontrolled or significant cardiac disease, including myocardial infarction or uncontrolled/unstable angina within 6 months prior to C1D1, CHF (New York Heart Association Class II to IV), uncontrolled or significant cardiac arrhythmia, or uncontrolled hypertension (resting systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg).
* Investigator judgment of 1 or more of the following:
* Mean resting corrected QTcF interval \> 470 ms , obtained from triplicate ECGs performed at screening.
* History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause Torsades de Pointes.
* Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.
* Leptomeningeal carcinomatosis.
* Clinically significant corneal disease.
* Known active tuberculosis infection
Prior/Concomitant Therapy
* Any of the following prior anticancer therapies:
* Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I
* TROP2-targeted therapy
* Prior treatment with same ICC agent
* Any concurrent anticancer treatment, with the exception of bisphosphonates, denosumab, for the treatment of bone metastases.
* Concurrent use of systemic hormonal replacement therapy (eg, estrogen). However, concurrent use of hormones for non-cancer related conditions (eg, insulin for diabetes) is acceptable.
* Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
* Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.
Prior/Concurrent Clinical Study Experience
* Previous treatment in the present study.
* Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dosing, randomization into a prior Dato-DXd or T-DXd (trastuzumab deruxtecan) study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.
* Participants with a known hypersensitivity to Dato-DXd, or any of the excipients of the product (including, but not limited to, polysorbate 80).
* Known history of severe hypersensitivity reactions to other monoclonal antibodies.
Other Exclusions
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
* For women only, currently pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Duarte, California, United States
Research Site
Los Angeles, California, United States
Research Site
Palo Alto, California, United States
Research Site
San Francisco, California, United States
Research Site
Jacksonville, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Grand Rapids, Michigan, United States
Research Site
New York, New York, United States
Research Site
Cleveland, Ohio, United States
Research Site
Portland, Oregon, United States
Research Site
Nashville, Tennessee, United States
Research Site
Richmond, Virginia, United States
Research Site
CABA, , Argentina
Research Site
CABA, , Argentina
Research Site
La Plata, , Argentina
Research Site
Mar del Plata, , Argentina
Research Site
Rosario, , Argentina
Research Site
Rosario, , Argentina
Research Site
Anderlecht, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Itajaí, , Brazil
Research Site
Jaú, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Ribeirão Preto, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
North York, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Baoding, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Bengbu, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Guangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Harbin, , China
Research Site
Jinan, , China
Research Site
Jinan, , China
Research Site
Linyi, , China
Research Site
Nanchang, , China
Research Site
Nanchang, , China
Research Site
Shanghai, , China
Research Site
Tianjin, , China
Research Site
Xiamen, , China
Research Site
Bezannes, , France
Research Site
Bordeaux, , France
Research Site
Lille, , France
Research Site
Lyon, , France
Research Site
Montpellier, , France
Research Site
Plérin, , France
Research Site
Toulouse, , France
Research Site
Villejuif, , France
Research Site
Heidelberg, , Germany
Research Site
Homburg, , Germany
Research Site
Leipzig, , Germany
Research Site
München, , Germany
Research Site
Ravensburg, , Germany
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Szekszárd, , Hungary
Research Site
Szolnok, , Hungary
Research Site
Gurgaon, , India
Research Site
Howrah, , India
Research Site
Hyderabad, , India
Research Site
Jaipur, , India
Research Site
Kolkata, , India
Research Site
Nashik, , India
Research Site
Surat, , India
Research Site
Visakhapatnam, , India
Research Site
Bologna, , Italy
Research Site
Candiolo, , Italy
Research Site
Florence, , Italy
Research Site
Meldola, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Padua, , Italy
Research Site
Prato, , Italy
Research Site
Roma, , Italy
Research Site
Chūōku, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukushima, , Japan
Research Site
Hiroshima, , Japan
Research Site
Isehara-shi, , Japan
Research Site
Kagoshima, , Japan
Research Site
Kashiwa, , Japan
Research Site
Kitaadachi-gun, , Japan
Research Site
Kōtoku, , Japan
Research Site
Kyoto, , Japan
Research Site
Matsuyama, , Japan
Research Site
Nagoya, , Japan
Research Site
Nishinomiya-shi, , Japan
Research Site
Osaka, , Japan
Research Site
Osakasayama-shi, , Japan
Research Site
Sapporo, , Japan
Research Site
Shinagawa-ku, , Japan
Research Site
Shinjuku-ku, , Japan
Research Site
Yokohama, , Japan
Research Site
Amsterdam, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Venlo, , Netherlands
Research Site
Bialystok, , Poland
Research Site
Gdansk, , Poland
Research Site
Gdynia, , Poland
Research Site
Konin, , Poland
Research Site
Koszalin, , Poland
Research Site
Lodz, , Poland
Research Site
Tomaszów Mazowiecki, , Poland
Research Site
Warsaw, , Poland
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
George, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Port Elizabeth, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Goyang-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
A Coruña, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Bilbao (Vizcaya), , Spain
Research Site
Huelva, , Spain
Research Site
L'Hospitalet de Llobregat, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Málaga, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Blackpool, , United Kingdom
Research Site
Bristol, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Colchester, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Nottingham, , United Kingdom
Research Site
Sutton, , United Kingdom
Research Site
Truro, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martinez Janez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2025 Jan 20;43(3):285-296. doi: 10.1200/JCO.24.00920. Epub 2024 Sep 12.
Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Janez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2024 Mar;20(8):423-436. doi: 10.2217/fon-2023-0188. Epub 2023 Jun 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509631-37-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-005620-12
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D9268C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.